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Abstract
PIK3C2A is a class II member of the phosphoinositide 3-kinase (PI3K) family that catalyzes
the phosphorylation of phosphatidylinositol (PI) into PI(3)P and the phosphorylation of
PI(4)P into PI(3,4)P2. At the cellular level, PIK3C2A is critical for the formation of cilia
and for receptor mediated endocytosis, among other biological functions. We identified
homozygous loss-of-function mutations in PIK3C2A in children from three independent
consanguineous families with short stature, coarse facial features, cataracts with sec-
ondary glaucoma, multiple skeletal abnormalities, neurological manifestations, among
other findings. Cellular studies of patient-derived fibroblasts found that they lacked
PIK3C2A protein, had impaired cilia formation and function, and demonstrated reduced
proliferative capacity. Collectively, the genetic and molecular data implicate mutations
in PIK3C2A in a new Mendelian disorder of PI metabolism, thereby shedding light on
the critical role of a class II PI3K in growth, vision, skeletal formation and neurological
development. In particular, the considerable phenotypic overlap, yet distinct features,
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between this syndrome and Lowe’s syndrome, which is caused by mutations in the PI-5-
phosphatase OCRL, highlight the key role of PI metabolizing enzymes in specific devel-
opmental processes and demonstrate the unique non-redundant functions of each
enzyme. This discovery expands what is known about disorders of PI metabolism and
helps unravel the role of PIK3C2A and class II PI3Ks in health and disease.
Author summary
Identifying the genetic basis of rare disorders can provide insight into gene function, sus-
ceptibility to disease, guide the development of new therapeutics, improve opportunities
for genetic counseling, and help clinicians evaluate and potentially treat complicated clini-
cal presentations. However, it is estimated that the genetic basis of approximately one-half
of all rare genetic disorders remains unknown. We describe one such rare disorder based
on genetic and clinical evaluations of individuals from 3 unrelated consanguineous fami-
lies with a similar constellation of features including short stature, coarse facial features,
cataracts with secondary glaucoma, multiple skeletal abnormalities, neurological manifes-
tations including stroke, among other findings. We discovered that these features were
due to deficiency of the PIK3C2A enzyme. PIK3C2A is a class II member of the phosphoi-
nositide 3-kinase (PI3K) family that catalyzes the phosphorylation of the lipids phosphati-
dylinositol (PI) into PI(3)P and the phosphorylation of PI(4)P into PI(3,4)P2 that are
essential for a variety of cellular processes including cilia formation and vesicle trafficking.
This syndrome is the first monogenic disorder caused by mutations in a class II PI3K fam-
ily member and thus sheds new light on their role in human development.
Introduction
Identifying the genetic basis of diseases with Mendelian inheritance provides insight into gene
function, susceptibility to disease, and can guide the development of new therapeutics. To
date, ~50% of the genes underlying Mendelian phenotypes have yet to be discovered [1]. The
disease genes that have been identified thus far have led to a better understanding of the patho-
physiological pathways and to the development of medicinal products approved for the clinical
treatment of such rare disorders [2]. Furthermore, technological advances in DNA sequencing
have facilitated the identification of novel genetic mutations that result in rare Mendelian dis-
orders [3,4]. We have applied these next-generation sequencing technologies to discover muta-
tions in PIK3C2A that cause a newly identified genetic syndrome consisting of dysmorphic
features, short stature, cataracts and skeletal abnormalities.
PIK3C2A is a class II member of the phosphoinositide 3-kinase (PI3K) family of lipid
kinases that catalyzes the phosphorylation of phosphatidylinositol (PI) [5]. PI3Ks are part of a
larger regulatory network of kinases and phosphatases that act upon the hydroxyl groups on
the inositol ring of PI to add or remove a phosphate group [6]. The combinatorial nature of
phosphorylation at the -3, -4, and -5 position of the inositol ring gives rise to seven different PI
species, termed polyphosphoinositides. Among these polyphosphoinositides, class II PI3Ks are
generally thought to catalyze the phosphorylation of PI and/or PI(4)P to generate PI(3)P and
PI(3,4)P2, respectively [7]. PI(3)P, PI(3,4)P2, and the other polyphosphoinositides each
account for less than ~1% of the total phospholipid content of a cell [8]. However, despite their
relatively low abundance, they play central roles in a broad array of signaling pathways and are
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central to the pathophysiology underlying cancer, metabolic disease, and host-pathogen inter-
actions [6].
The functions of class II PI3Ks are poorly understood relative to many other kinases and
phosphatases that regulate PI metabolism, in part because there was no causal link between
any class II PI3K and a monogenic human disease. In contrast, a number of disorders of PI
metabolism have previously been described that have provided invaluable insight into the
physiological functions of specific PI metabolizing enzymes [9]. These include Charcot-Marie-
Tooth type 4J (FIG4) [10,11], Centronuclear X-linked myopathy (MTM1) [12], and primary
immunodeficiency (PIK3CD) [13,14], among others. As just one example, detailed studies of
FIG4 subsequent to its identification as a cause of Charcot-Marie-Tooth type 4J have revealed
both genetic and physiological interactions with VAC14 and PIKFYVE, which together gener-
ate PI(3,5)P2 and are required for melanosome homeostasis, oligodendrocyte differentiation,
and remyelination [15–18]. Collectively, the array of PI metabolism disorders is striking for its
phenotypic diversity, affecting a wide range of organ systems including those described above
as well as others that lead to neuromuscular, skeletal, renal, eye, growth, and immune disor-
ders. The diversity of phenotypic manifestations resulting from PI metabolism defects high-
lights the lack of functional redundancy between genes that regulate nominally the same
enzymatic transformation of PIs.
PIK3C2A has previously been attributed a wide-range of biological functions including glu-
cose transport, angiogenesis, Akt activation, endosomal trafficking, phagosome maturation,
mitotic spindle organization, exocytosis, and autophagy [19–28]. In addition, PIK3C2A is crit-
ical for the formation and function of primary cilia [23,26]. However, as mentioned above,
there is as yet no link between PIK3C2A or any class II PI3K and a Mendelian disorder. Here,
we describe the evidence that homozygous loss-of-function mutations in PIK3C2A cause a
novel syndromic disorder involving neurological, visual, skeletal, growth, and occasionally
hearing impairments.
Results
Five individuals between the ages of 8 and 21 from three unrelated consanguineous families
were found by diagnostic analyses to have a similar constellation of clinical features including
dysmorphic facial features, short stature, skeletal and neurological abnormalities, and cataracts
(Fig 1, Table 1, S1 Table). The dysmorphic facial features included coarse facies, low hairline,
epicanthal folds, flat and broad nasal bridges, and retrognathia (S1 Table). Skeletal findings
included scoliosis, delayed bone age, diminished ossification of femoral heads, cervical lordo-
sis, shortened fifth digits with mild metaphyseal dysplasia and clinodactyly, as well as dental
findings such as broad maxilla incisors, narrow mandible teeth, and enamel defects (Fig 1B
and 1C, S1 Table, S1 Fig). Most of the affected individuals exhibited neurological involvement
including developmental delay and stroke. This was first seen in individual I-II-2 when she
recently started having seizures, with an EEG demonstrating sharp waves in the central areas
of the right hemisphere and short sporadic generalized epileptic seizures. Her brain MRI
showed a previous stroke in the right corpus striatum (Fig 1E). Hematological studies were
normal for hypercoagulability and platelet function (S2 Table). In addition, brain MRI of
patient II-II-3 showed multiple small frontal and periventricular lacunar infarcts (S1E Fig).
Unclear episodes of syncope also led to neurological investigations including EEG in individ-
ual III-II-2, without any signs of epilepsy. Her brain MRI showed symmetrical structures and
normal cerebrospinal fluid spaces but pronounced lesions of the white matter (S1E Fig). Other
recurrent features included hearing loss, secondary glaucoma, and nephrocalcinosis.
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Fig 1. Pedigrees and pictures of the individuals studied. (A) Pedigree of three consanguineous families studied. Black boxes indicated affected
individuals. Roman numerals indicating the generation are on the left and Arabic numerals indicating the individual are below each pedigree
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In addition to the shared syndromic features described above in all three families, both
affected daughters in Family I were diagnosed with congenital adrenal hyperplasia (CAH), due
to 17-alpha-hydroxylase deficiency, and were found to have a homozygous familial mutation:
NM_000102.3:c.286C>T; p.(Arg96Trp) in the CYP17A1 gene (OMIM #202110) [29,30]. The
affected individuals in Families II and III do not carry mutations in CYP17A1 or have CAH,
suggesting the presence of two independent and unrelated conditions in Family I. The co-
occurrence of multiple monogenic disorders is not uncommon among this highly consanguin-
eous population [31].
To identify the genetic basis of this disorder, enzymatic assays related to the mucopolysac-
charidosis subtypes MPS I, MPS IVA, MPS IVB, and MPSVI were tested in Families I and II
and found to be normal. Enzymatic assays for mucolipidosis II/III were also normal and no
pathogenic mutations were found in galactosamine-6-sulfate sulfatase (GALNS) in Family I.
Additionally, since some of the features of patient II-II-3 were reminiscent of Noonan syn-
drome, Hennekam syndrome, and Aarskog-Scott syndrome, individual genes involved in
these disorders were analyzed in Family II, but no pathogenic mutation was identified. In
patient III-II-2, Williams-Beuren syndrome was excluded in childhood. Additionally, direct
molecular testing at presentation in adulthood excluded Leri-Weill syndrome, Alstrom dis-
ease, and mutations in FGFR3.
symbol. Genotypes are indicated below each individual with a “+” indicating a wild-type allele and a “-” indicating a mutant allele as illustrated in
Fig 1G. The genotypes of individuals II-II-1, II-II-4, and II-II-5 are omitted at the family’s request. (B) Photographs of affected individuals under
their corresponding pedigree symbol indicating coarse facial features including a broad nasal bridge, thick columella, and thick alae nasi.
Representative images are shown of (C) an X-ray indicating square shaped vertebral bodies and a flat pelvis, subluxation of the hips, and meta- and
epiphyseal dysplasia of the femoral heads in patient III-II-2, (D) the teeth in patient II-II-3 indicating broad maxilla incisors, narrow mandible
teeth, and dental enamel defects, (E) the eye with a visible cataract (Cataracta polaris anterior), as indicated by a white arrow, in individual III-II-2,
and (F) a brain MRI demonstrating areas of altered signal intensity as indicated by the white arrow in individual I-II-2. (G) Diagram of the intron/
exon and protein domain structures of PIK3C2A indicating the location of mutations identified in the pedigrees shown in Fig 1A.
https://doi.org/10.1371/journal.pgen.1008088.g001
Table 1. Phenotypic characteristics of PIK3C2A deficient patients.
Family I I II II III
Patient II-1 II-2 II-2 II-3 II-2
Age (years) 13 8 12 10 20
Gender female female male male female
Origin Israel (Muslim-Arabic) Israel (Muslim-Arabic) Syria Syria Tunisia
Consanguineous + + + + +
Height -3.3 SD -2.3 SD -2.5 SD -4.8 SD -2.5 SD
Weight -0.2 SD -1.7 SD -0.2 SD -3.9 SD -1.9 SD
Head circumference -0.25 SD N.D. +0.9 SD -1.1 SD +0.5 SD
Congenital cataract + + + + +
Secondary glaucoma + + + + -
Hearing loss + - - + +
Scoliosis/skeletal abnormalities + + + + +
Teeth abnormalities + + + + +
Developmental delay + + N.D. N.D. N.D.
Elevated urine MPS levels + N.D. + + N.D.
"+" indicates presence of trait, "-" indicates absence of trait, N.D., not done.
https://doi.org/10.1371/journal.pgen.1008088.t001
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Given the negative results of targeted genetic testing, WES and CNV analysis was per-
formed for the affected individuals from all three families. Five homozygous candidate variants
were identified in Family I, including the CYP17A1 (p.Arg96Trp) mutation that is the cause of
the CAH [29,30], but is not known to cause the other phenotypes. The remaining four variants
affected the genes ATF4, DNAH14, PLEKHA7, and PIK3C2A (S3 Table). In Family II, homo-
zygous missense variants were identified in KIAA1549L, METAP1, and PEX2, in addition to
a homozygous deletion in PIK3C2A that encompassed exons 1–24 out of 32 total exons (S3
Table). The deletion was limited to PIK3C2A and did not affect the neighboring genes.
Sequence analysis of Family III showed a homozygous missense variant in PTH2R, nonsense
variant in DPRX, and splice site variant in PIK3C2A (S3 Table).
Sequencing analyses revealed that all affected family members in the Families I, II, and III
were homozygous for predicted loss-of-function variants in PIK3C2A, and none of the unaf-
fected family members were homozygous for the PIK3C2A variants (Fig 1A and 1G). The ini-
tial link between these three families with rare mutations in PIK3C2A was made possible
through the sharing of information via the GeneMatcher website [3]. The PIK3C2A deletion in
Family II was confirmed by multiplex amplicon quantification (S2A Fig). The single nucleo-
tide PIK3C2A variants in Families I and III were confirmed by Sanger sequencing (S2B and
S2C Fig).
In Family I, the nonsense mutation in PIK3C2A (p.Tyr195�) truncates 1,492 amino acids
from a protein that is 1,686 amino acids. This is predicted to eliminate nearly all functional
domains including the catalytic kinase domain, and is expected to trigger nonsense-mediated
mRNA decay [25]. Accordingly, levels of PIK3C2A mRNA are significantly decreased in both
heterozygous and homozygous individuals carrying the p.Tyr195� variant (Fig 2A). The deletion
in Family II eliminates the first 24 exons of the 32-exon PIK3C2A gene and is thus predicted to
cause a loss of protein expression. This is consistent with a lack of PIK3C2A mRNA expression
(Fig 2B). The variant in PIK3C2A in Family III affects an essential splice site (c.1640+1G>T)
that leads to decreased mRNA levels (Fig 2C). Deep sequencing of the RT-PCR products
revealed 4 alternative transcripts in patient-derived lymphocytes (p.[Asn483_Arg547delinsLys,
Ala521Thrfs�4, Ala521_Glu568del, and Arg547SerinsTyrIleIle�]) of which the transcript encod-
ing p. Asn483_Arg547delinsLys that skips both exons 5 and 6 was also observed in patient’s
fibroblasts (S3 Fig). Although this transcript remains in-frame, no PIK3C2A protein was
detected by Western blotting (Fig 2D and 2F). This is consistent with Families I and II, for which
Western blotting also failed to detect any full-length PIK3C2A in fibroblasts from the affected
homozygous children (Fig 2E and 2F). Thus, all three PIK3C2A variants likely encode loss-of-
function alleles. Importantly, among the 141,456 WES and whole genome sequences from con-
trol individuals in the Genome Aggregation Database (gnomAD v2.1) [32], none are homozy-
gous for loss-of-function mutations in PIK3C2A, which is consistent with total PIK3C2A
deficiency causing severe early onset disease.
To test whether the observed loss-of-function mutations in PIK3C2A cause cellular pheno-
types consistent with loss of PIK3C2A function, we examined PI metabolism, cilia formation
and function, and cellular proliferation rates. PIK3C2A deficiency in the patient-derived fibro-
blasts decreased the levels of PI(3,4)P2 throughout the cell (Fig 3A) as well as decreased the lev-
els of PI(3)P at the ciliary base (Figs 3B and S4A). The reduction in PI(3)P at the ciliary base
was associated with a reduction in ciliary length (Fig 4A), although the percentage of ciliated
cells was not altered (Fig 4B). Additional cilia defects include a reduction in the levels of
RAB11 at the ciliary base (Figs 4C and S4B), which functions within a GTPase cascade culmi-
nating in the activation of RAB8, which together with ARL13B selectively traffics ciliary pro-
teins to the cilium [33]. Additionally, there was increased accumulation of IFT88 along the
length of the cilium (Figs 4D and S4C), which is a component of the intraflagellar transport
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sub-complex IFT-B, and is essential for the trafficking of ciliary protein cargoes along the axo-
nemal microtubules [34,35]. Together, these findings are suggestive of defective trafficking of
ciliary components. Finally, the proliferative capacity of PIK3C2A deficient cells was reduced
relative to control cells (Fig 5).
Fig 2. Protein and mRNA levels of PIK3C2A in patient-derived cells. PIK3C2A mRNA levels were detected by
qRT-PCR in patient derived fibroblasts from (A) Family I, (B) Family II, and (C) Family III. The WT sample in Fig 2A is
based on n = 1 individual, the WT sample in Fig 2B is based on n = 3 individuals, and the WT sample in Fig 2C is based
on n = 1 individual, totaling n = 5 different WT samples. qRT-PCR data is represented as mean ± SEM (n = 3–4 technical
replicates per sample). (D, E) Whole cell lysates from fibroblasts of healthy controls (WT), heterozygous parents, and
affected individuals from (D) Family III and (E) Families I and II were analyzed by Western blotting for PIK3C2A and
the loading controls Actin or GAPDH. Immunogen of anti-PIK3C2A antibodies (AB1-AB4) are detailed in S5 Table. (F)
Densitometry of Western blot results was performed using ImageJ. Individual samples are shown with the data combined
from the four different PIK3C2A antibodies used, with the exception of the WT samples which includes fibroblasts from
two individuals. � indicates p< 0.05. �� indicates p< 0.01. ��� indicates p< 0.0001.
https://doi.org/10.1371/journal.pgen.1008088.g002
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As PIK3C2A is a member of the class II PI3K family, we tested whether the expression of
the other family members PIK3C2B and PIK3C2G were altered by PIK3C2A deficiency. The
expression of PIK3C2G was not detected by qRT-PCR in either patient-derived or control pri-
mary fibroblasts. This is consistent with the relatively restricted expression pattern of this gene
in the GTEx portal [36], with expression largely limited to stomach, skin, liver, esophagus,
mammary tissue, and kidney, but absent in fibroblast cells and most other tissues. In contrast,
PIK3C2B expression was detected, with both mRNA and protein levels significantly increased
in PIK3C2A deficient cells (Fig 6A–6D). Downregulation of PIK3C2A using an inducible
shRNA in HeLa cells also resulted in elevated levels of PIK3C2B (Fig 6E). Together, these data
are consistent with increased levels of PIK3C2B serving to partially compensate for PIK3C2A
deficiency.
Discussion
Here we describe the identification of three independent families with homozygous loss-of-
function mutations in PIK3C2A resulting in a novel syndrome consisting of short stature, cata-
racts, secondary glaucoma, and skeletal abnormalities among other features. Patient-derived
fibroblasts had decreased levels of PI(3,4)P2 and PI(3)P, shortening of the cilia and impaired
Fig 3. Impaired PI metabolism in patient-derived fibroblasts. Quantification of PI(3,4)P2 and PI(3)P were analysed
and normalized on whole cell fluorescence. (A) Immunofluorescence analysis of cellular PI(3,4)P2 levels. Results
showed that PI(3,4)P2 is significantly reduced throughout the cell in -/- cells compared with +/+ cells. n = 4
independent experiments and 10 cells per genotype for each experiment (S6 Table). (B) Immunofluorescence analysis
of PI(3)P localization at the base of the primary cilium. Results showed that PI(3)P is significantly reduced at the base
of the primary cilium in -/- cells compared with +/+ and or +/- cells. n = 3 independent experiments and 15 cells per
genotype for each experiment (S6 Table). Nuclei are stained with DAPI. �� indicates p< 0.01. ��� indicates p< 0.0001.
https://doi.org/10.1371/journal.pgen.1008088.g003
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Fig 4. Ciliary defects due to PIK3C2A deficiency in patient-derived fibroblasts. (A) Cilia length and (B) cilia
number were determined in primary fibroblasts from two affected individuals and three unrelated controls. Data is
represented as mean ± SEM (n>300/sample). Raw data for cilia length is provided in S6 Table. (C) Immunofluorescence
analysis of RAB11 localization at the base of the primary cilium. Results showed that RAB11 is significantly reduced at
the base of the primary cilium in -/- cells compared with +/+ and or +/- cells. n = 3 independent experiments and 15 cells
Mutations in PIK3C2A cause syndromic short stature
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ciliary protein localization, and reduced proliferation capacity. Thus, based on the loss-of-
function mutations in PIK3C2A, the phenotypic overlap between the three independent fami-
lies, and the patient-derived cellular data consistent with previous studies of PIK3C2A func-
tion, we conclude that loss-of-function mutations in PIK3C2A cause this novel syndrome.
The identification of PIK3C2A loss-of-function mutations in humans represents the first
mutations identified in any class II PI-3-kinase in a disorder with a Mendelian inheritance,
and thus sheds light into the biological role of this poorly understood class of PI3Ks [7,37].
This is significant not only for understanding the role of PIK3C2A in rare monogenic disor-
ders, but also the potential contribution of common variants in PIK3C2A in more genetically
complex disorders. There are now numerous examples where severe mutations in a gene cause
a rare Mendelian disorder, whereas more common variants in the same gene, with a less dele-
terious effect on protein function, are associated with polygenic human traits and disorders
[38–40]. For example, severe mutations in PPARG cause monogenic lipodystrophy, whereas
less severe variants are associated with complex polygenic forms of lipodystrophy [41,42]. In
the case of PIK3C2A deficiency, the identification of various neurological features including
developmental delay, selective mutism, and the brain abnormalities detected by MRI (S1
per genotype for each experiment. (D) Immunofluorescence analysis of IFT88 localization within the primary cilia.
Results showed that IFT88 is significantly increased along the primary cilium in -/- cells compared with +/+ and or +/-
cells, suggesting a defective trafficking of ciliary components. n = 3 independent experiments and 15 cells per genotype
for each experiment. Quantification of IFT88 and RAB11 were normalized on whole cell fluorescence. ��� indicates
p< 0.0001.
https://doi.org/10.1371/journal.pgen.1008088.g004
Fig 5. PIK3C2A deficiency causes delayed proliferation rates in patient-derived fibroblasts. Proliferation curve of
primary fibroblasts isolated from PIK3C2A WT (+/+), heterozygous (+/-), and homozygous (-/-) individuals. Values
are reported as the mean ± SEM from 3 independent experiments. � indicates p< 0.05, ��� indicates p< 0.0001.
https://doi.org/10.1371/journal.pgen.1008088.g005
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Table) may provide biological insight into the mechanisms underlying the association between
common variants in PIK3C2A and schizophrenia [43–45].
Other monogenic disorders of phosphoinositide metabolism include Lowe’s syndrome and
Joubert syndrome, which can be caused by mutations in the inositol polyphosphate 5-phos-
phatases OCRL and INPP5E, respectively [46]. All three of these disorders of PI metabolism
affect some of the same organ systems, namely the brain, eye, and kidney. However, the phe-
notype associated with mutations in INPP5E is quite distinct, and includes cerebellar vermis
hypo-dysplasia, coloboma, hypotonia, ataxia, and neonatal breathing dysregulation [47]. In
contrast, the phenotypes associated with Lowe’s syndrome share many of the same features
with PIK3C2A deficiency including congenital cataracts, secondary glaucoma, kidney defects,
skeletal abnormalities, developmental delay, and short stature [9,48]. The enzyme defective in
Lowe’s syndrome, OCRL, is functionally similar to PIK3C2A as well, as it is also required for
membrane trafficking and ciliogenesis [49]. The similarities between Lowe’s syndrome and
PIK3C2A deficiency suggest that similar defects in phosphatidylinositol metabolism may
underlie both disorders. In addition to Lowe’s syndrome, there is partial overlap between
Fig 6. PIK3C2B levels are increased by PIK3C2A deficiency. PIK3C2B mRNA levels were detected by qRT-PCR in (A) Family I, (B) Family II, and (C)
Family III. qRT-PCR data is represented as mean ± SEM (n = 3 technical replicates per sample). The WT sample in Fig 6A is based on n = 1 and the WT
sample in Fig 6B is based on n = 3, totaling n = 4 different WT samples. (D) PIK3C2B protein levels were detected by Western blotting in Family I from 2
independent experiments. (E) PIK3C2A and PIK3C2B protein levels were analyzed in HeLa cells by Western blotting following doxycycline inducible
shRNA mediated knockdown of PIK3C2A. Data shown is representative from 3 independent experiments. � indicates p< 0.05, �� indicates p< 0.01. ���
indicates p< 0.0001.
https://doi.org/10.1371/journal.pgen.1008088.g006
Mutations in PIK3C2A cause syndromic short stature
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008088 April 29, 2019 11 / 21
PIK3C2A deficiency and yet other Mendelian disorders of PI metabolism such as the early-
onset cataracts in patients with INPP5K deficiency [50,51], demonstrating the importance of
PI metabolism in lens development.
The viability of humans with PIK3C2A deficiency is in stark contrast to mouse Pik3c2a
knockout models that result in growth retardation by e8.5 and embryonic lethality between
e10.5–11.5 due to vascular defects [20]. One potential explanation for this discrepancy is func-
tional differences between human PIK3C2A and the mouse ortholog. However, the involve-
ment of both human and mouse PIK3C2A in cilia formation, PI metabolism, and cellular
proliferation suggests a high degree of functional conservation at the cellular level [26,28]. An
alternate possibility is that the species viability differences associated with PIK3C2A deficiency
result from altered compensation from other PI metabolizing enzymes. For instance, there are
species-specific differences between humans and mice in the transcription and splicing of the
OCRL homolog INPP5B that may uniquely contribute to PI metabolism in each species [52].
Alternately, PIK3C2B levels were significantly increased in human PIK3C2A deficient cells,
including both patient-derived cells and HeLa cells surviving PIK3C2A deletion, suggesting
that this may partially compensate for the lack of PIK3C2A in humans, although it remains to
be determined whether a similar compensatory pathway exists in mice.
It is intriguing that both PIK3C2A and OCRL have important roles in primary cilia formation
[26,53,54]. Primary cilia are evolutionary conserved microtubule-derived cellular organelles that
protrude from the surface of most mammalian cell types. Primary cilia formation is initiated by
a cascade of processes involving the targeted trafficking and docking of Golgi-derived vesicles
near the mother centriole. They play a pivotal role in a number of processes, such as left-right
patterning during embryonic development, cell growth, and differentiation. Abnormal phospha-
tidylinositol metabolism results in ciliary dysfunction [55], including loss of PIK3C2A that
impairs ciliogenesis in mouse embryonic fibroblasts, likely due to defective trafficking of ciliary
components [26]. The importance of primary cilia in embryonic development and tissue homeo-
stasis has become evident over the two past decades, as a number of proteins which localize to
the cilium harbor defects causing syndromic diseases, collectively known as ciliopathies [56,57].
Hallmark features of ciliopathies share many features with PIK3C2A deficiency and include skel-
etal abnormalities, progressive vision and hearing loss, mild to severe intellectual disabilities,
polydactyly, and kidney phenotypes. Many of these disorders, including Bardet-Biedl Syndrome,
Meckel Syndrome, and Joubert Syndrome are also associated with decreased cilium length [58],
as seen in PIK3C2A deficient cells. Ciliary length is a function of both axoneme elongation and
cilium disassembly, and is molecularly regulated by intraflagellar protein transport, including
the velocity of transport and cargo loading, as well as soluble tubulin levels and microtubule
modifications [59,60]. As defects in intraflagellar protein transport were likely indicated by
abnormal IFT88 localization along the length of the cilium in PIK3C2A deficient cells, this may
represent a potential mechanism underlying the shortened cilium. Further work and the identifi-
cation of additional patients with mutations in PIK3C2A will continue to improve our under-
standing of the genotype-phenotype correlation associated with PIK3C2A deficiency. However,
the identification of the first patients with PIK3C2A deficiency establishes a role for PIK3C2A in
neurological and skeletal development, as well as vision, and growth and implicates loss-of-func-
tion PIK3C2A mutations as a potentially new cause of a cilia-associated disease.
Materials and methods
Ethics statement
The study was approved by the Helsinki Ethics Committees of Rambam Health Care Campus
(#0038-14-RMB), the University Hospital Institutional Review Board for Case Western
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Reserve University (#NHR-15-39), the Ethics Committee of the Friedrich-Alexander Univer-
sity Erlangen-Nu¨rnberg (#164_15 B), and was in accordance with the regulations of the Uni-
versity Medical Center Groningen’s ethical committee. Written informed consent was
obtained from all participants.
Whole exome sequencing
Whole exome sequencing (WES) of two patients from Family I was performed using DNA
(1μg) extracted from whole blood and fragmented and enriched using the Truseq DNA PCR
Free kit (Illumina). Samples were sequenced on a HiSeq2500 (Illumina) with 2x100bp read
length and analyzed as described [61]. Raw fastq files were mapped to the reference human
genome GRCh37 using BWA [62] (v.0.7.12). Duplicate reads were removed by Picard (v.
1.119) and local realignment and base quality score recalibration was performed following the
GATK pipeline [63] (v. 3.3). The average read depth was 98x (I-II-1) and 117x (I-II-2). Haplo-
typeCaller was used to call SNPs and indels and variants were further annotated with Annovar
[64]. Databases used in Annovar were RefSeq [65], Exome Aggregation Consortium (ExAC)
[32] (v. exac03), ClinVar [66] (v. clinvar_20150330) and LJB database [67] (v. ljb26_all).
Exome variants in Family I were filtered out if they were not homozygous in both affected
individuals, had a population allele frequency greater than 0.1% in either the ExAC database
[32] or the Greater Middle East Variome Project [68], and were not predicted to be deleterious
by either SIFT [69] or Polyphen2 [70].
Whole exome sequencing was performed on the two affected individuals of Family II and
both their parents essentially as previously described [71]. Target regions were enriched using
the Agilent SureSelectXT Human All Exon 50Mb Kit. Whole-exome sequencing was per-
formed on the Illumina HiSeq platform (BGI Europe) followed by data processing with BWA
[62] (read alignment) and GATK [63] (variant calling) software packages. Variants were anno-
tated using an in-house developed pipeline. Prioritization of variants was done by an in-house
designed ‘variant interface’ and manual curation.
The DNAs of Family III were enriched using the SureSelect Human All Exon Kit v6 (Agi-
lent) and sequenced on an Illumina HiSeq 2500 (Illumina). Alignment, variant calling, and
annotation were performed as described [72]. The average read depth was 95x (III-II-2), 119x
(III-I-1) and 113x (III-I-2). Variants were selected that were covered by at least 10% of the
average coverage of each exome and for which at least 5 novel alleles were detected from 2 or
more callers. All modes of inheritance were analyzed [72]. Variants were prioritized based on
a population frequency of 10−3 or below (based on the ExAC database [32] and an in-house
variant database), on the evolutionary conservation, and on the mutation severity prediction.
All candidate variants in Families I, II, and III were confirmed by Sanger sequencing (prim-
ers listed in S4 Table).
Copy number variant (CNV) analysis
Microarray analysis for CNV detection in Family I was performed using a HumanOmni5--
Quad chip (Illumina). SNP array raw data was mapped to the reference human genome
GRCh37 and analyzed using GenomeStudio (v. 2011/1). Signal intensity files with Log R ratio
and B-allele frequency were further analyzed with PennCNV [73] (v. 2014/5/7). In Family III
the diagnostic chromosomal microarray analysis was performed with an Affymetrix CytoScan
HD-Array and analyzed using Affymetrix Chromosome analysis Suite-Software, compared
with the Database of Genomic Variants and 820 in house controls. All findings refer to UCSC
Genome Browser on Human, February 2009 Assembly (hg19), Human Genome built 37.
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CNV analysis on the WES data of Families II and III were performed using CoNIFER [74].
Variants were annotated using an in-house developed pipeline. Prioritization of variants was
done by an in-house designed ‘variant interface’ and manual curation as described before [75].
Subsequent segregation analysis of the pathogenic CNV in Family II was performed with
MAQ by using a targeted primer set with primers in exons 3, 10, 20 and 24 which are located
within the deletion and exons 28, 32, 34 which are located outside of the deletion (Multiplex
Amplicon Quantification (MAQ); Multiplicom).
Cell culture
Human dermal fibroblasts were obtained from sterile skin punches cultured in DMEM (Dul-
becco’s Modified Eagle’s Medium) supplemented with 10–20% Fetal Calf Serum, 1% Sodium
Pyruvate and 1% Penicillin and streptomycin (P/S) in 5% CO2 at 37˚C. Control fibroblasts
were obtained from healthy age-matched volunteers. Fibroblasts from passages 4–8 were used
for the experiments. To measure cell proliferation, cells were detached using trypsin and
counted with an Automated Cell Counter (ThermoFisher). Cells (n = 2500) were plated in
triplicate in 96-well plates. Viability was measured at day 2, 4, 6 and 8. Each measurement was
normalized to day 0 (measured the day after plating) and expressed as a fold increase. Viability
was assessed by using CellTiter-Glo Luminescent Cell Viability Assay (Promega). Three inde-
pendent experiments were performed.
Inducible knockdown of PIK3C2A
HeLa cells were infected with lentiviral particles containing pLKO-TET-PI3KC2A-shRNA or
pLKO-TET-scramble-shRNA in six-well plates (n = 50,000 cells). After two days, the medium
containing lentiviral particles was replaced with DMEM 10% FBS, 1.5μg/ml puromycin. After
7 days of selection, cells were detached and 100,000 cells were plated in six-well plates in tripli-
cate in the presence of doxycycline (0.5, 1 and 2 μg/ml). Medium containing doxycycline was
replaced every 48 hours. After 10 days of doxycycline treatment, cells were lysed and analysed
by Western blot.
cDNA and quantitative real time-PCR
Total RNA was purified from primary fibroblasts using the PureLink RNA purification kit
(ThermoFisher) or RNAPure peqGOLD (Peqlab). RNA was reverse transcribed into comple-
mentary DNA with random hexamer using a high-Capacity cDNA Reverse Transcription Kit
(ThermoFisher). RT-PCR from lymphocytes to detect exon-skipping in family III was per-
formed using primers flanking exon 6. The resulting product was sequenced on an Illumina
HiSeq2500 (Illumina) to detect splicing variants with high sensitivity. Gene expression was
quantified by SYBR Green real-time PCR using the CFX Connect Real-Time System (BioRad).
Primers used are detailed in S4 Table. Expression levels were calculated using the ΔΔCT
method relative to GADPH.
Western blotting
Protein was extracted from cultured primary fibroblast cells as described [76,77]. Extracts
were quantified using the DC protein assay (BioRad) or the BCA method. Equal amounts of
protein were separated by SDS-PAGE and electrotransferred onto polyvinylidene difluoride
membranes (Millipore). Membranes were blocked with TBST/5% fat-free dried milk and
stained with antibodies as detailed in S5 Table. Secondary antibodies were goat anti-rabbit
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(1:5,000, ThermoFisher #31460) goat anti-mouse (1:5,000, ThermoFisher #31430), goat anti-
rabbit (1:2,000, Dako #P0448), and goat anti-mouse (1:2,000, Dako #P0447).
Immunostaining
Primary fibroblasts were grown on glass coverslips to approximately 80% - 90% confluency in
DMEM + 10% FCS + 1% P/S, at which time the medium was replaced with DMEM without
FCS for 48 hours to induce ciliogenesis. Cells were fixed in either methanol for 10 minutes at
-20˚C or 4% paraformaldehyde for 10 minutes at room temperature (RT). Fixed cells were
washed in PBS, and incubated with 10% normal goat serum, 1% bovine serum albumin in PBS
for 1 hour at RT. If cells were fixed with paraformaldehyde, blocking solutions contained 0.5%
Triton X-100. Cells were incubated with primary antibody overnight at 4˚C, washed in PBS,
and incubated with secondary antibody including 4’,6-diamidino-2-Phenylindole (DAPI) to
stain nuclei for 1 hours at RT. Coverslips were mounted on glass slides with fluoromount (Sci-
ence Services) and imaged on a confocal laser scanning system with a 63x objectives (LSM 710,
Carl Zeiss MicroImaging). Primary antibodies are detailed in S5 Table.
Cilia analysis
To induce ciliogenesis, cells were grown in DMEM with 0–0.2% FCS for 48 hours. Cells were
washed in PBS, then fixed and permeabilized in ice-cold methanol for 5 minutes, followed by
extensive washing with PBS. After blocking in 5% Bovine Serum Albumin, cells were incu-
bated with primary antibodies for 1.5 hours at RT and extensively washed in PBS-T. Primary
antibodies used for Centrin and ARL13B are detailed in S5 Table. To wash off the primary
antibody, cells were extensively washed in PBS-T. Subsequently, cells were incubated with sec-
ondary antibodies, Alexa Flour 488 (1:800, Invitrogen) and Alexa Fluor 568 (1:800, Invitro-
gen), for 45 min followed by washing with PBS-T. Finally, cells were shortly rinsed in ddH2O
and samples were mounted using Vectashield with DAPI. Images were taken using an Axio
Imager Z2 microscope with an Apotome (Zeiss) at 63x magnification. Cilia were measured
manually using Fiji software taking the whole length of the cilium based on ARL13B staining.
At least 300 cilia were measured per sample. Cilia lengths were pooled for 3 control cell lines
and compare to 2 patient-derived samples (II-II-2 and II-II-3). Statistical significance was cal-
culated using a Student t-test. PI(3)P at the ciliary base was detected in randomly chosen cells
using the same exposure for each acquisition. A specific anti-PI(3)P antibody (Echelo Z-P003)
was used to quantify the PI(3)P by measuring the green fluorescent intensity around the ciliary
base in a region with a diameter of 8 μm and a depth of 10 μm as previously illustrated and
described [26].
Supporting information
S1 Fig. Images of individuals with PIK3C2A deficiency. Photographic images of (A) teeth,
(B) hands, and (C) feet are shown from the five individuals with PIK3C2A deficiency. (D)
X-Ray images of the pelvis and (E) MRI images of the brain are shown when available. White
arrows in the MRI images indicate regions of altered signal intensity.
(TIF)
S2 Fig. Homozygous loss-of-function mutations in PIK3C2A. (A) CNV analysis confirmed
a homozygous deletion encompassing exons 1–24 out of 32 total exons of PIK3C2A, indicated
with the red line (B) Sanger sequencing confirmed homozygosity for the PIK3C2A c.585T vari-
ant in Family I. (C) Sanger sequencing confirmed homozygosity for the PIK3C2A c.1640+1
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G>T variant in Family III.
(TIF)
S3 Fig. The c.1650+1G>T mutation in PIK3C2A disrupts the splice donor site in intron 6.
(A) Deep sequencing of RT-PCR products revealed 4 alternative transcripts in lymphocytes
(red lines) compared to control samples (blue lines): �: r.1561_1704del; p.Ala521_Glu568del,
��: r. 1640_1641ins1640+1_1640+27; p. Arg547SerinsTyrIleIle�, ���: r.1561_1640del; p.
Ala521Thrfs�4, ����: r.1449_1640del; p.Asn483_Arg547delinsLys. Exon/intron structure of
PIK3C2A (exons: yellow boxes) with transcripts of the patient of family III compared to con-
trols. (B) Example of sequenced RT-PCR products from cDNA of fibroblasts from wild-type
control and the patient of family III using primers located in exons 3 and 10. Skipping of
exons 5 and 6 is the result of the mutation. Positions of primers are indicated by orange arrows
and position of the splice site mutation is indicated by a black arrow.
(TIF)
S4 Fig. Quantification of fluorescence in patient-derived fibroblasts. Quantification of fluo-
rescence intensity for (A) PI(3)P at the ciliary base, (B) RAB11 at the ciliary base, and (C) cili-
ary IFT88. Data is shown separately for each individual family as indicated.
(TIF)
S1 Table. Detailed phenotypic characteristics of patients in Families I, II, and III.
(XLSX)
S2 Table. Hematological evaluation of patients in Family I.
(XLSX)
S3 Table. Homozygous candidate variants identified by whole exome sequencing.
(XLSX)
S4 Table. List of primers used in this study.
(XLSX)
S5 Table. List of antibodies used in this study.
(XLSX)
S6 Table. Raw data underlying Fig 3 and Fig 4A.
(XLSX)
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